Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cerilliant
Queensland Health
Moodys
Dow
Covington
Fish and Richardson
Julphar
Argus Health
Accenture

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,066,980

« Back to Dashboard

Which drugs does patent 9,066,980 protect, and when does it expire?

Patent 9,066,980 protects ALOXI and is included in one NDA.

Protection for ALOXI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in forty countries.
Summary for Patent: 9,066,980
Title:Liquid pharmaceutical formulations of palonosetron
Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
Inventor(s): Calderari; Giorgio (Rancate, CH), Bonadeo; Daniele (Casalzuigno, IT), Cannella; Roberta (Varese, IT), Macciocchi; Alberto (Melide, CH), Miksztal; Andrew (Palo Alto, CA), Malefyt; Thomas (Carmel Valley, CA), Lee; Kathleen M (Palo Alto, CA)
Assignee: Helsinn Healthcare SA (Lugano/Pazzallo, CH) Roche Palo Alto LLC (Palo Alto, CA)
Application Number:13/902,299
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use;

Drugs Protected by US Patent 9,066,980

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-001 Jul 25, 2003 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,066,980

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,598,218 Liquid pharmaceutical formulations of palonosetron ➤ Subscribe
9,439,854 Liquid pharmaceutical formulations of palonosetron ➤ Subscribe
7,947,724 Liquid pharmaceutical formulations of palonosetron ➤ Subscribe
9,125,905 Liquid pharmaceutical formulations of palonosetron ➤ Subscribe
9,457,020 Liquid pharmaceutical formulations of palonosetron ➤ Subscribe
9,457,021 Liquid pharmaceutical formulations of palonosetron ➤ Subscribe
7,947,725 Liquid pharmaceutical formulations of palonosetron ➤ Subscribe
8,598,219 Liquid pharmaceutical formulations of palonosetron ➤ Subscribe
8,518,981 Liquid pharmaceutical formulations of palonosetron ➤ Subscribe
7,960,424 Liquid pharmaceutical formulations of palonosetron ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,066,980

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 90449 ➤ Subscribe
Taiwan I342212 ➤ Subscribe
Taiwan 200418517 ➤ Subscribe
Tunisia SN05180 ➤ Subscribe
Slovenia 1601359 ➤ Subscribe
Serbia 20050578 ➤ Subscribe
Portugal 1601359 ➤ Subscribe
Poland 378398 ➤ Subscribe
Peru 00662005 ➤ Subscribe
Panama 8594801 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Mallinckrodt
Harvard Business School
AstraZeneca
Novartis
Boehringer Ingelheim
McKinsey
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot